U.S. Markets closed

How Might the Immunic Combination with Vital Therapies Impact Investors

NEW YORK, NY / ACCESSWIRE / April 10, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Vital Therapies, Inc. (VTL) is a biotherapeutic company, focused on developing cell-based therapies for the treatment of acute forms of liver failure.

Vital Therapies announced that its stockholders voted to approve the proposals required to complete the business combination with Immunic AG at a special meeting of Vital Therapies stockholders held Friday.

On Friday, April 5, 2019, VTL shares opened at $.26 per share and reached a high of $.70 per share before closing at $.51 on traded volume of 154.5 million shares.

Get more details about the VTL business combination and potential new products READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/vital-therapies/

In September 2018, VTL reported top-line data from a phase 3 clinical trial of ELAD, VTL-308, in 151 subjects with severe alcoholic hepatitis. Although there was a numerical improvement in survival in the ELAD-treated group between three months and one year following randomization, the study failed to meet the primary endpoint of a significant improvement in overall survival through at least ninety-one days. The secondary endpoint of the proportion of survivors at study day ninety-one also showed no statistically significant difference between the groups. The company consequently discontinued the ELAD program.

Find out more about Immunic and review the FYE 2018 financial results here READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/vital-therapies/

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: editor@tradersnewssource.com

SOURCE: Traders News Source



View source version on accesswire.com:
https://www.accesswire.com/541432/How-Might-the-Immunic-Combination-with-Vital-Therapies-Impact-Investors